Management of Platelet Refractoriness
Diagnosis and Initial Management
- Patients with confirmed alloimmune platelet refractoriness should receive HLA-A and HLA-B matched platelets as first-line therapy, with platelet cross-matching reserved for those who fail HLA-matched products or cannot be HLA-typed 1, 2
- Require at least two consecutive ABO-compatible platelet transfusions that both produce poor increments 1, 2, 3
- Measure platelet counts 1 hour post-transfusion to calculate the corrected count increment (CCI) 4
- Define poor response as CCI <5,000 or absolute increment <2,000/unit of pooled platelets (or <10,000 for apheresis platelets) 2, 3
Distinguishing Immune from Non-Immune Causes
- Order HLA class I antibody testing on all refractory patients to confirm alloimmunization 1, 2
- Approximately 90% of alloimmunized patients have anti-HLA antibodies detectable by standard assays 1, 2, 4
- Non-immune causes that mimic refractoriness include splenomegaly or hypersplenism 7, disseminated intravascular coagulation (DIC) 3, active hemorrhage 7, and drug-induced antibodies 1
Management Algorithm for Confirmed Alloimmune Refractoriness
- Provide HLA-A and HLA-B matched platelets from typed donor registries 1, 7, 2
- Success rate: 50-60% of transfusion events produce adequate increments 7, 8
- Single-antigen mismatches may still produce satisfactory increments in 75% of cases 7, 8
- For patients who fail HLA-matched platelets, use platelet cross-matching techniques to identify compatible donors 1, 2
Transfusion Strategy for Refractory Patients
- Transfuse alloimmunized patients ONLY for active bleeding, not prophylactically 7, 8
- Reserve limited HLA-matched/cross-matched inventory for therapeutic (not prophylactic) indications 7, 8
Prevention Considerations
- Leukoreduction of blood products reduces HLA alloimmunization rates from 50% to 3-4% in at-risk populations (no reference, as per instructions to ignore [ignore ref])